Comparison of oral and vaginal misoprostol for cervical ripening before manual vacuum aspiration of first trimester pregnancy under local anesthesia: a randomized placebo-controlled study.
The objective of this prospective randomized placebo-controlled study was to determine the effectiveness of 400 mug oral and 400 mug vaginal misoprostol administration for cervical priming 3 h prior to manual vacuum aspiration (MVA) under local anesthesia for voluntary termination of pregnancy before 10 weeks of gestation in comparison with placebo oral or placebo vaginal administration (n=40 in each group). Postmedication cervical dilatation was similar in the oral (mean, 6.6+/-1.5) and vaginal (mean, 7.2+/-0.8) misoprostol groups but significantly higher compared with the oral (mean, 3.4+/-0.2) and vaginal (mean, 3.6+/-1.9) placebo groups. Duration of the procedure was also significantly shorter in the misoprostol groups in comparison with their placebo counterparts. Preoperative bleeding and side effects were more common in the misoprostol groups, but none required medical intervention. Intraoperative bleeding was less in the vaginal misoprostol group compared with the placebo groups. There was no significant difference in terms of visual analogue scores during the procedure, patient satisfaction, days of postoperative bleeding and rate of postoperative complications among the groups. Cervical priming with misoprostol administered orally or vaginally 3 h before MVA for termination of pregnancy under local anesthesia facilitates the procedure by decreasing the need for cervical dilatation and by shortening its duration without improving patients' pain perception and satisfaction mainly due to side effects.
Cakir
Leyla
L
Family Planning Clinic, SSK (Social Security Organization) Maternity and Women's Health Training Hospital, 06010 Ankara, Turkey.
Dilbaz
Berna
B
Caliskan
Eray
E
Dede
F Suat
FS
Dilbaz
Serdar
S
Haberal
Ali
A
D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage*; D000028:Abortion, Induced; D000282:Administration, Intravaginal; D000284:Administration, Oral; D000328:Adult; D000772:Anesthesia, Local; D020070:Cervical Ripening; D005260:Female; D006801:Humans; D016595:Misoprostol / Q000008:administration & dosage*; D010919:Placebos; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D014421:Turkey; D014619:Vacuum Curettage
D000020:Abortifacient Agents, Nonsteroidal; D010919:Placebos; D016595:Misoprostol